| Objective: To systematically review the risk factors of Borderline Ovarian Tumors(BOTs)after conservative surgery,providing the basis for clinical treatment and follow-up.Methods: Databases including Pub Med,EMbase,The Cochrane Library(Issue 12,2016),Web of Science,CNKI,CBM,Wan Fang Data and VIP were searched from inception to December31 th 2016,to collect relevant cohort studies or case-control studies on the recurrent risk factors of BOTs after conservative surgery.Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies according to the inclusion and exclusion criteria.Then,Meta-analysis was performed using Rev Man 5.3 software.Results: A total of 20 cohort studies involving 1064 patients were included.The results of meta-analysis showed that,for the postoperative recurrence rate,there was significant difference between FIGO≥Ⅱ and FIGO Ⅰ[OR=3.32,95%CI(1.56,7.05),P=0.002],bilateral ovarian tumors and unilateral ovarian tumors [OR=3.51,95%CI(1.73,7.10),P=0.0005],ovarian cystectomy and unilateral adnexectomy [OR=2.88,95%CI(1.82,4.56),P<0.00001],tumor rupture and non-tumor rupture[OR=8.93,95%CI(2.73,29.20),P=0.0003],Serous Borderline Ovarian Tumor(SBOT)and Mucinous Borderline Ovarian Tumors(MBOT)[OR=2.21,95%CI(1.49,3.28),P<0.0001],micropapillary and non-micropapillary [OR=2.36,95%CI(1.32,4.24),P=0.004].But there was no significant difference between FIGO ⅠC and FIGO≤ⅠB [OR=1.32,95%CI(0.74,2.33),P=0.34],elevated CA125 and normal CA125 before operation [OR=1.37,95%CI(0.53,3.53),P=0.51],Laparoscopy and Laparotomy [OR=1.27,95%CI(0.88,1.85),P=0.20],staging and unstaging[OR=0.38,95%CI(0.11,1.26),P=0.11],lymphadnectomy and non-lymphadnectomy [OR=1.21,95%CI(0.34,4.30),P=0.77],stromal microinvasion and non-stromal microinvasion [OR=1.25,95%CI(0.69,2.25),P=0.46],adjuvant chemotherapy and non-adjuvant chemotherapy [OR=1.12,95%CI(0.43,2.90),P=0.81].Conclusion: Meta-analysis showed that FIGO≥Ⅱ,bilateral ovarian tumors,tumor rupture,SBOT,micropapillary are the risk factors of borderline ovarian tumors after conservative surgery. |